Actinium Pharmaceuticals, Inc. to Present at Oppenheimer's 33rd Annual Healthcare Conference
NEW YORK, March 15, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced that the Company's management team will participate in a virtual presentation at Oppenheimer's 33rd Annual Healthcare Conference being held March 13-17, 2023. The presentation will include recent Company highlights including positive results from its pivotal Phase 3 SIERRA trial of Iomab-B and development opportunities for Actimab-A under the recently signed Cooperative Research and Development Agreement with the National Cancer Institute (NCI).
A replay of the presentation will be available on the Company's IR section of the website for 90 days after the event: https://ir.actiniumpharma.com/
About Oppenheimer 33rd Annual Healthcare Conference
This conference will provide investors a broad spectrum of public and private healthcare companies spanning all major sectors of the healthcare industry: bio & specialty pharmaceuticals; biotechnology; medical devices; life science tools and diagnostics; healthcare information technology and distribution; and healthcare providers and servicers.
The Healthcare ecosystem has never been as complex nor as full of opportunities. Therapies and treatments are evolving more rapidly than investors have been able to keep up with. The 33rd Annual Oppenheimer Healthcare Conference will showcase nearly 300 companies that will likely shape the industry for the next decade to come.
For more information on the conference, please visit: https://www.oppenheimer.com/events/2023/33rd-annual-healthcare-conference.aspx
About Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing targeted radiotherapies to deliver cancer-killing radiation with cellular level precision to treat patients with high unmet needs. Actinium's clinical pipeline is led by targeted radiotherapies that are being applied to targeted conditioning, which is intended to selectively deplete a patient's disease or cancer cells and certain immune cells prior to a bone marrow transplant (BMT), gene therapy or adoptive cell therapy, such as CAR-T, to enable engraftment of these transplanted cells with minimal toxicities. Our lead product candidate, Iomab-B (I-131 apamistamab) has been studied in over four hundred patients, including the pivotal Phase 3 Study of Iomab-B in Elderly Relapsed or Refractory Acute Myeloid Leukemia (SIERRA) trial for BMT conditioning. The SIERRA trial was positive with Iomab-B meeting the primary endpoint of durable Complete Remission of 6-months with high statistical significance (p<0.0001). Iomab-B enabled 100% of patients to access a BMT and produced higher rates of post-BMT CR. Iomab-B produced positive results for the secondary endpoints of the SIERRA trial including reducing the probability of an event by 78% resulting in an Event-Free Survival (EFS) Hazard Ratio of 0.22 (p<0.0001), doubled 1-year overall survival and median overall survival. Iomab-ACT, low dose I-131 apamistamab, is being studied as a targeted conditioning agent in a Phase 1 study with a CD19 CAR T-cell Therapy with Memorial Sloan Kettering Cancer Center with NIH funding. Actimab-A, our second most advanced product candidate has been studied in approximately 150 patients with Acute Myeloid Leukemia or AML, including in combination trials with the chemotherapy regimen CLAG-M and with venetoclax, a targeted therapy. Actimab-A or lintuzumab-Ac225 is an Actinium-225 based antibody radiation conjugate targeting CD33, a validated target in AML. Actinium has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) to develop Actimab-A as a single agent or combination with chemotherapy, targeted agents or immunotherapy in Phase 1, 2 or 3 trials. The NCI will fund clinical trial expenses under the CRADA while Actinium will supply Actimab-A. The NCI is currently accepting proposals for non-clinical and clinical studies with Actimab-A. Actinium is a pioneer and leader in the field of Actinium-225 alpha therapies with an industry leading technology platform comprising over 190 patents and patent applications including methods of producing the radioisotope AC-225. Our technology and expertise have enabled collaborative research partnerships with Astellas Pharma, Inc. for solid tumor theranostics, with AVEO Oncology Inc. to create an Actinium-225 HER3 targeting radiotherapy for solid tumors, and with EpicentRx, Inc. to create targeted radiotherapy combinations with their novel, clinical stage small molecule CD47-SIRPα inhibitor. Approximate cash balance of $100 million as of February 27, 2023 is unaudited and may be subject to future revision. More information is available on Actinium's website: https://www.actiniumpharma.com/.
View original content to download multimedia:https://www.prnewswire.com/news-releases/actinium-pharmaceuticals-inc-to-present-at-oppenheimers-33rd-annual-healthcare-conference-301772560.html
SOURCE Actinium Pharmaceuticals, Inc.
Company Codes: AMEX:ATNM, NYSE:NYSE, AMEX:NYSE